Pelvic Chemoradiotherapy (CRT) could allow sufficient local control in order to avoid major and sometimes mutilating surgery. View / Download Pdf Share at Facebook Abstractīackground: In unresectable metastatic rectal cancers, surgery of primary tumor remains highly debated. Journal of Cancer Science and Clinical Therapeutics 5 (2021): 334-346. A Phase I dose escalation trial using Intensity-Modulated Radiotherapy with simultaneous integrated boost in Pelvic Chemoradiotherapy for Metastatic Rectal Cancer. Thibaut Lizée, Valérie Seegers, Julien Blanchecotte, Emmanuel Rio, Olivier Capitain, Véronique Guérin-Meyer, Florence Legouté, Damien Autret, Marc-André Mahé, Amaury Paumier. Received: 15 June 2021 Accepted: 12 July 2021 Published: 09 August 2021
*Corresponding Author: Amaury Paumier, Institut de Cancérologie de l’Ouest, 15 Rue André Bocquel, 49055 Angers, France. Thibaut Lizée 1, Valérie Seegers 2, Julien Blanchecotte 1, Emmanuel Rio 3, Olivier Capitain 4, Véronique Guérin-Meyer 4, Florence Legouté 1, Damien Autret 5, Marc-André Mahé 6, Amaury Paumier 1ġRadiation oncology department, Institut de Cancérologie de l’Ouest, Angers, FranceĢClinical research department, Institut de Cancérologie de l’Ouest - site Paul Papin, Angers, Franceģ Radiation oncology department, Institut de Cancérologie de l’Ouest, Saint-Herblain, FranceĤMedical oncology Department, Institut de Cancérologie de l’Ouest, Angers, FranceĥRadiation physics department, Institut de Cancérologie de l’Ouest, Angers, France
A Phase I dose escalation trial using Intensity-Modulated Radiotherapy with simultaneous integrated boost in Pelvic Chemoradiotherapy for Metastatic Rectal Cancer Article Information
0 kommentar(er)
